T-PLL
MCID: TCL005
MIFTS: 48

T-Cell Prolymphocytic Leukemia (T-PLL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for T-Cell Prolymphocytic Leukemia

MalaCards integrated aliases for T-Cell Prolymphocytic Leukemia:

Name: T-Cell Prolymphocytic Leukemia 20 58 29 6 17 70
T-Cell Chronic Lymphocytic Leukemia 58
Lymphocytic Leukemia T-Cell Chronic 54
T Cell Prolymphocytic Leukemia 20
Leukemia, T-Cell, Chronic 70
T-Pll 58

Characteristics:

Orphanet epidemiological data:

58
t-cell prolymphocytic leukemia
Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 32 C91.6
MESH via Orphanet 45 D015461
ICD10 via Orphanet 33 C91.6
UMLS via Orphanet 71 C0023494 C2363142
Orphanet 58 ORPHA86871
UMLS 70 C0023494 C2363142

Summaries for T-Cell Prolymphocytic Leukemia

MalaCards based summary : T-Cell Prolymphocytic Leukemia, also known as t-cell chronic lymphocytic leukemia, is related to prolymphocytic leukemia and telangiectasis. An important gene associated with T-Cell Prolymphocytic Leukemia is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are ERK Signaling and Human cytomegalovirus infection. The drugs alemtuzumab and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, spleen and myeloid, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 T-cell-prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia with aggressive behavior and... more...

Related Diseases for T-Cell Prolymphocytic Leukemia

Diseases in the B Cell Prolymphocytic Leukemia family:

T-Cell Prolymphocytic Leukemia

Diseases related to T-Cell Prolymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
# Related Disease Score Top Affiliating Genes
1 prolymphocytic leukemia 30.8 TCL1A MYC MTCP1 JAK3 JAK1 HLA-S
2 telangiectasis 30.7 VEGFA CHEK2 ATM
3 t-cell lymphoblastic leukemia/lymphoma 30.6 TCL1A NFKB1 MYC MTCP1 CD7
4 adult t-cell leukemia 30.5 MYC JAK3 CD7
5 ataxia-telangiectasia 30.4 TCL1A MTCP1 CHEK2 C11orf65 ATM ABL1
6 b cell prolymphocytic leukemia 30.4 MYC MS4A1
7 b-cell lymphoma 30.2 TCL1A MYC MS4A1 CDKN1B ATM
8 peripheral t-cell lymphoma 30.2 TCL1A MS4A1 JAK3
9 leukemia 30.1 TCL1A MYC MTCP1 JAK3 JAK1 CHEK2
10 precursor t-cell acute lymphoblastic leukemia 30.0 TCL1A MYC CD7 ABL1
11 nijmegen breakage syndrome 29.9 MYC CHEK2 ATM
12 sezary's disease 29.9 MYC JAK3 CD7 CD52
13 leukemia, acute lymphoblastic 29.8 TCL1A MYC JAK3 JAK1 CD7 ABL1
14 leukemia, chronic lymphocytic 29.6 VEGFA TCL1A MYC MS4A1 CD7 CD52
15 t-cell acute lymphoblastic leukemia 29.5 MYC JAK3 JAK1 CDKN1B ATM ABL1
16 myelodysplastic syndrome 28.9 VEGFA MYC CHEK2 ATM ABL1
17 leukemia, acute myeloid 28.5 VEGFA MYC JAK3 JAK1 CHEK2 CDKN1B
18 leukemia, t-cell, chronic 10.8
19 splenomegaly 10.7
20 lymphoproliferative syndrome 10.6
21 chromosomal triplication 10.6
22 diffuse large b-cell lymphoma 10.4
23 t-cell lymphoma 1a 10.4
24 ataxia and polyneuropathy, adult-onset 10.4
25 lymphoma 10.4
26 chromosome 8q duplication 10.4
27 kaposi sarcoma 10.3
28 exanthem 10.3
29 thrombocytopenia 10.3
30 purpura 10.3
31 bile duct cystadenoma 10.3 CHEK2 ATM
32 maxillary sinus adenocarcinoma 10.3 CDKN1B ATM
33 central nervous system leukemia 10.2 CD7 ABL1
34 jak3-deficient severe combined immunodeficiency 10.2 JAK3 JAK1
35 t-cell large granular lymphocyte leukemia 10.2
36 sarcoma 10.2
37 neutropenia 10.2
38 hematologic cancer 10.2
39 spindle cell sarcoma 10.2
40 hemolytic anemia 10.2
41 b-cell growth factor 10.2
42 pure red-cell aplasia 10.2
43 agammaglobulinemia 10.2
44 b-cell non-hodgkin lymphoma 10.2 MS4A1 ATM
45 lymphoma aids related 10.2 TCL1A MYC
46 familial ovarian cancer 10.2 CHEK2 C11orf65 ATM
47 leukemia, chronic lymphocytic 2 10.2 MS4A1 ATM
48 corpus callosum lipoma 10.2 SMARCB1 CHEK2
49 cerebral hemisphere lipoma 10.2 SMARCB1 CHEK2
50 pityriasis lichenoides 10.2 MS4A1 CD7

Graphical network of the top 20 diseases related to T-Cell Prolymphocytic Leukemia:



Diseases related to T-Cell Prolymphocytic Leukemia

Symptoms & Phenotypes for T-Cell Prolymphocytic Leukemia

GenomeRNAi Phenotypes related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.02 ABL1 MYC SMARCB1
2 Decreased viability GR00221-A-2 10.02 ABL1 CHEK2 SMARCB1
3 Decreased viability GR00221-A-3 10.02 ABL1 ATM CHEK2 JAK3 MYC SMARCB1
4 Decreased viability GR00221-A-4 10.02 ATM CHEK2
5 Decreased viability GR00249-S 10.02 MYC SMARCB1
6 Decreased viability GR00342-S-1 10.02 ABL1
7 Decreased viability GR00342-S-2 10.02 ABL1 CHEK2
8 Decreased viability GR00342-S-3 10.02 ABL1
9 Decreased viability GR00381-A-1 10.02 SMARCB1
10 Decreased viability GR00402-S-2 10.02 JAK3 MYC
11 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 9.43 ATM CDKN1B JAK1
12 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.33 ATM CHEK2 JAK3
13 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 NFKB1
14 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 ABL1 ATM NFKB1
15 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.28 ATM C11orf65 CDKN1B CHEK2 NFKB1

MGI Mouse Phenotypes related to T-Cell Prolymphocytic Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 ABL1 ATM CD7 CDKN1B CHEK2 JAK1
2 endocrine/exocrine gland MP:0005379 9.96 ABL1 ATM CD7 CDKN1B CHEK2 JAK1
3 immune system MP:0005387 9.8 ABL1 ATM CD7 CDKN1B CHEK2 JAK1
4 neoplasm MP:0002006 9.17 ATM CDKN1B CHEK2 KLRB1 MYC SMARCB1

Drugs & Therapeutics for T-Cell Prolymphocytic Leukemia

Drugs for T-Cell Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
alemtuzumab Approved, Investigational Phase 2 216503-57-0
2
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
3
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
4
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
5
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
6
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
7 Antineoplastic Agents, Immunological Phase 2
8 Immunologic Factors Phase 2
9 Analgesics Phase 2
10 Antirheumatic Agents Phase 2
11 Immunosuppressive Agents Phase 2
12 Antiviral Agents Phase 2
13 Alkylating Agents Phase 2
14 Anti-Infective Agents Phase 2
15 Antimetabolites Phase 2
16 Immunoglobulins Phase 1
17 Antibodies Phase 1
18 Immunoglobulins, Intravenous Phase 1
19 Antibodies, Monoclonal Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase II Trial of Combined Immunochemotherapy With Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients With Previously Treated or Untreated T-Prolymphocytic Leukemia Completed NCT01186640 Phase 2 Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab;Alemtuzumab
2 Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia Completed NCT00278213 Phase 2 cyclophosphamide;fludarabine phosphate;mitoxantrone hydrochloride
3 A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia Recruiting NCT03873493 Phase 2 Venetoclax;Ibrutinib
4 A Phase IIa Study Evaluating the Pharmacokinetics, Safety and Efficacy of APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With Relapsed/Refractory T-cell Prolymphocytic Leukemia (R/R T-PLL) Not yet recruiting NCT04496349 Phase 2 APG-115;APG-2575
5 Phase II Study of Bortezomib (VELCADE) for the Treatment of Relapsed or Refractory T-cell Prolymphocytic Leukemia Withdrawn NCT01162031 Phase 2 Velcade
6 Phase Ib Pilot Study of Itacitinib With Alemtuzumab in Patients With T-Cell Prolymphocytic Leukemia (T-PLL) Recruiting NCT03989466 Phase 1 Itacitinib
7 Registry of the German CLL Study Group Long Term Follow-up of Patients With CLL, B-PLL, T-PLL, SLL,T or NK-LGL, HCL and Richter's Transformation Recruiting NCT02863692

Search NIH Clinical Center for T-Cell Prolymphocytic Leukemia

Genetic Tests for T-Cell Prolymphocytic Leukemia

Genetic tests related to T-Cell Prolymphocytic Leukemia:

# Genetic test Affiliating Genes
1 T-Cell Prolymphocytic Leukemia 29

Anatomical Context for T-Cell Prolymphocytic Leukemia

MalaCards organs/tissues related to T-Cell Prolymphocytic Leukemia:

40
Bone Marrow, Spleen, Myeloid, Bone, T Cells, Colon, Liver

Publications for T-Cell Prolymphocytic Leukemia

Articles related to T-Cell Prolymphocytic Leukemia:

(show top 50) (show all 464)
# Title Authors PMID Year
1
Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. 6 61
9334731 1997
2
Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. 6 61
9288106 1997
3
Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. 6
16958054 2006
4
Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer. 6
12195425 2002
5
ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. 6
9463314 1998
6
A high frequency of distinct ATM gene mutations in ataxia-telangiectasia. 6
8808599 1996
7
ATM mutations in cancer families. 6
8797579 1996
8
Mutations associated with variant phenotypes in ataxia-telangiectasia. 6
8755918 1996
9
Role of TCL1 and ALL1 in human leukemias and development. 61 54
10197596 1999
10
Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. 61
33654067 2021
11
Optic nerve biopsy in leukemic infiltrative optic neuropathy: a case report and review of the literature. 61
33557696 2021
12
T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches. 61
33728186 2021
13
T-cell Prolymphocytic Leukemia, Cerebriform Variant. 61
33732560 2021
14
Cutaneous Presentation of T-Cell Prolymphocytic Leukemia Mimicking Dermatomyositis. 61
33606377 2021
15
T-cell prolymphocytic leukemia: Insidious onset followed by aggressive course with cutaneous involvement. 61
33599388 2021
16
The miR-200c/141-ZEB2-TGFβ axis is aberrant in human T-cell prolymphocytic leukemia. 61
33596640 2021
17
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. 61
33598678 2021
18
A Complex Karyotype in a 68-Year-Old Patient With T-PLL. 61
33684910 2021
19
What to Look Out for when Transplanting T-Cell Prolymphocytic Leukemia. 61
32369824 2021
20
Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia. 61
32259827 2021
21
T-Cell Prolymphocytic Leukemia: Long-Term Remissions Challenging! 61
32392564 2021
22
Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling. 61
33301031 2020
23
Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia. 61
32875608 2020
24
Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma. 61
32970500 2020
25
TCL1 and TCR collaborate to drive T-PLL. 61
33301037 2020
26
Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways. 61
33543866 2020
27
Non-canonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling. 61
32959065 2020
28
T-cell prolymphocytic leukemia: Review of an entity and its differential diagnostic considerations. 61
32543075 2020
29
Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene. 61
32247279 2020
30
Epstein-Barr virus-positive diffuse large B-cell lymphoma after sustained remission of T-cell prolymphocytic leukemia with alemtuzumab. 61
31960738 2020
31
Generalized pruritic dark papules in a patient with T-cell prolymphocytic leukemia - a clinicopathological challenge. 61
31515798 2020
32
A Rare Association: Autoimmune Hemolytic Anemia With Indolent T-Cell Prolymphocytic Leukemia. 61
32523849 2020
33
Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia. 61
31677197 2020
34
Advances and Perspectives in the Treatment of T-PLL. 61
32034661 2020
35
Sensitizing the interdisciplinary team to desensitizations: An alemtuzumab case report. 61
31390960 2020
36
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. 61
32012154 2020
37
First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). 61
31566032 2020
38
Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia. 61
32040552 2020
39
CHORIOCAPILLARIS FLOW VOIDS IN CRYPTOCOCCAL CHOROIDITIS USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. 61
29373342 2020
40
CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia. 61
33110606 2020
41
Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration. 61
32802528 2020
42
Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia. 61
33117517 2020
43
Complete remission of aggressive T-cell LGL leukemia with pentostatin therapy: first case report. 61
33437844 2020
44
Atypical Mature T-Cell Neoplasms: The Relevance of the Role of Flow Cytometry. 61
32848413 2020
45
Direct Targeting Options for STAT3 and STAT5 in Cancer. 61
31817042 2019
46
Bilateral tonsillar infiltration of T-cell prolymphocytic leukemia. 61
31788291 2019
47
JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL. 61
31766351 2019
48
Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia. 61
31698446 2019
49
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. 61
31292114 2019
50
T-PLL: harmonizing criteria for research. 61
31582368 2019

Variations for T-Cell Prolymphocytic Leukemia

ClinVar genetic disease variations for T-Cell Prolymphocytic Leukemia:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ATM , C11orf65 NM_000051.3(ATM):c.7271T>G (p.Val2424Gly) SNV Pathogenic 3023 rs28904921 GRCh37: 11:108199929-108199929
GRCh38: 11:108329202-108329202
2 ATM , C11orf65 NM_001330368.2(C11orf65):c.641-22822_641-22814del Deletion Pathogenic 3019 rs587776547 GRCh37: 11:108202612-108202620
GRCh38: 11:108331885-108331893
3 ATM NM_000051.3(ATM):c.5044G>C (p.Asp1682His) SNV Pathogenic 3026 rs121434217 GRCh37: 11:108170479-108170479
GRCh38: 11:108299752-108299752
4 ATM NM_000051.3(ATM):c.5309C>G (p.Ser1770Ter) SNV Pathogenic 3042 rs121434223 GRCh37: 11:108172506-108172506
GRCh38: 11:108301779-108301779

Copy number variations for T-Cell Prolymphocytic Leukemia from CNVD:

7 (show top 50) (show all 758)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14323 1 107060000 118270000 Deletion T-cell prolymphocytic leukemia
2 17205 1 141501392 142732360 Amplification T-cell prolymphocytic leukemia
3 19890 1 151880356 153088354 Deletion T-cell prolymphocytic leukemia
4 22015 1 164099958 164243756 Amplification T-cell prolymphocytic leukemia
5 24296 1 178292024 178520303 Amplification T-cell prolymphocytic leukemia
6 25710 1 193462805 193618427 Deletion T-cell prolymphocytic leukemia
7 26226 1 198221297 245353397 Amplification T-cell prolymphocytic leukemia
8 29813 1 236310000 236970000 Deletion T-cell prolymphocytic leukemia
9 31328 1 26860573 29239576 Deletion T-cell prolymphocytic leukemia
10 35233 1 6146230 6344245 Deletion T-cell prolymphocytic leukemia
11 35791 1 67452671 99313693 Deletion T-cell prolymphocytic leukemia
12 36896 1 825852 120863833 Amplification T-cell prolymphocytic leukemia
13 39073 10 108954534 111745117 Deletion T-cell prolymphocytic leukemia
14 39204 10 111824569 135311386 Amplification T-cell prolymphocytic leukemia
15 40780 10 133604797 135311386 Deletion T-cell prolymphocytic leukemia
16 41072 10 135165535 135311386 Amplification T-cell prolymphocytic leukemia
17 41217 10 148946 135311386 Amplification T-cell prolymphocytic leukemia
18 41219 10 148946 5692243 Deletion T-cell prolymphocytic leukemia
19 41413 10 17718148 22325377 Deletion T-cell prolymphocytic leukemia
20 41736 10 23032969 39064552 Deletion T-cell prolymphocytic leukemia
21 41964 10 26990000 30260000 Deletion T-cell prolymphocytic leukemia
22 42441 10 34110000 35980000 Deletion T-cell prolymphocytic leukemia
23 43355 10 46363383 47154881 Amplification T-cell prolymphocytic leukemia
24 44297 10 54778135 56318960 Deletion T-cell prolymphocytic leukemia
25 45076 10 67100000 71360000 Deletion T-cell prolymphocytic leukemia
26 46742 10 85720790 86922140 Deletion T-cell prolymphocytic leukemia
27 47214 10 90488702 94393578 Deletion T-cell prolymphocytic leukemia
28 48517 11 100045570 103051410 Deletion T-cell prolymphocytic leukemia
29 49138 11 10330000 11140000 Deletion T-cell prolymphocytic leukemia
30 49397 11 106417979 114849006 Deletion T-cell prolymphocytic leukemia
31 49494 11 107346114 107685623 Deletion T-cell prolymphocytic leukemia
32 49495 11 107346114 108015771 Deletion T-cell prolymphocytic leukemia
33 49502 11 107401046 107685623 Deletion T-cell prolymphocytic leukemia
34 49503 11 107419503 108193907 Deletion T-cell prolymphocytic leukemia
35 49515 11 107511257 108661992 Deletion T-cell prolymphocytic leukemia
36 49523 11 107598768 107745036 Deletion ATM T-cell prolymphocytic leukemia
37 49774 11 110891599 111596604 Deletion T-cell prolymphocytic leukemia
38 50371 11 117492601 119996648 Deletion T-cell prolymphocytic leukemia
39 50952 11 120493810 122186945 Deletion T-cell prolymphocytic leukemia
40 51031 11 122000000 131630000 Gain T-cell prolymphocytic leukemia
41 24451 1 180754716 183730500 Amplification T-cell prolymphocytic leukemia
42 31215 1 26102907 26936965 Deletion T-cell prolymphocytic leukemia
43 31214 1 26102907 26624823 Deletion T-cell prolymphocytic leukemia
44 31149 1 25598247 25881984 Deletion T-cell prolymphocytic leukemia
45 51124 11 123252803 123608170 Deletion T-cell prolymphocytic leukemia
46 51271 11 124529138 125115632 Deletion T-cell prolymphocytic leukemia
47 51421 11 125855565 126161131 Deletion T-cell prolymphocytic leukemia
48 51521 11 127437820 128227400 Deletion T-cell prolymphocytic leukemia
49 51526 11 127525578 128328976 Deletion T-cell prolymphocytic leukemia
50 51529 11 127550030 128131996 Deletion T-cell prolymphocytic leukemia

Expression for T-Cell Prolymphocytic Leukemia

Search GEO for disease gene expression data for T-Cell Prolymphocytic Leukemia.

Pathways for T-Cell Prolymphocytic Leukemia

Pathways related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 VEGFA NFKB1 MYC JAK3 JAK1 CHEK2
2
Show member pathways
12.92 VEGFA SAMHD1 NFKB1 MYC JAK1 ATM
3
Show member pathways
12.81 NFKB1 MYC JAK3 JAK1 CDKN1B
4
Show member pathways
12.81 NFKB1 MYC JAK3 JAK1 CDKN1B
5
Show member pathways
12.79 NFKB1 MYC JAK3 JAK1 ABL1
6 12.79 VEGFA NFKB1 MYC JAK3 JAK1 CDKN1B
7
Show member pathways
12.77 VEGFA NFKB1 MYC JAK1 CDKN1B ABL1
8
Show member pathways
12.76 NFKB1 MYC JAK3 JAK1 CDKN1B
9
Show member pathways
12.64 VEGFA TCL1A NFKB1 MYC MTCP1 JAK3
10 12.5 VEGFA NFKB1 MYC CDKN1B ATM ABL1
11 12.49 CHEK2 CDKN1B BRCC3 ATM
12
Show member pathways
12.42 VEGFA NFKB1 MYC JAK1 CDKN1B ABL1
13
Show member pathways
12.39 VEGFA NFKB1 JAK3 JAK1
14
Show member pathways
12.38 NFKB1 MYC JAK3 JAK1 CDKN1B
15
Show member pathways
12.36 CHEK2 BRCC3 ATM ABL1
16
Show member pathways
12.36 MYC CHEK2 CDKN1B ATM ABL1
17 12.34 MYC CHEK2 CDKN1B ATM ABL1
18
Show member pathways
12.33 VEGFA NFKB1 MYC JAK1
19 12.29 NFKB1 JAK3 JAK1 CDKN1B
20
Show member pathways
12.28 VEGFA NFKB1 JAK3 JAK1 CDKN1B
21 12.25 NFKB1 MYC CDKN1B ATM
22
Show member pathways
12.25 SAMHD1 MYC JAK1 ATM ABL1
23 12.18 VEGFA NFKB1 MYC JAK1
24 12.14 NFKB1 MYC CHEK2 ATM
25 12.14 NFKB1 MYC JAK3 JAK1 CHEK2 ATM
26 11.97 VEGFA MYC JAK3 JAK1
27 11.9 VEGFA NFKB1 CDKN1B
28
Show member pathways
11.86 NFKB1 JAK3 JAK1
29 11.85 NFKB1 MYC CDKN1B
30 11.83 MYC CDKN1B ABL1
31 11.83 NFKB1 MYC CDKN1B ATM ABL1
32
Show member pathways
11.82 CHEK2 ATM ABL1
33
Show member pathways
11.8 SMARCB1 CHEK2 ATM
34 11.73 MYC CDKN1B ATM
35 11.69 MYC JAK1 CDKN1B
36
Show member pathways
11.69 NFKB1 MYC CDKN1B
37 11.67 MYC CHEK2 ATM
38
Show member pathways
11.67 NFKB1 MYC JAK3 JAK1
39 11.62 CHEK2 ATM ABL1
40
Show member pathways
11.61 NFKB1 MYC JAK1 CDKN1B
41 11.59 SMARCB1 CDKN1B ABL1
43 11.52 VEGFA NFKB1 MYC JAK1
44 11.5 NFKB1 MYC JAK1
45 11.49 NFKB1 CHEK2 ATM
46 11.49 MYC CDKN1B ATM ABL1
47 11.47 NFKB1 MYC CDKN1B ATM ABL1
48 11.44 VEGFA NFKB1 MYC CDKN1B
49
Show member pathways
11.38 MYC JAK3 JAK1 CDKN1B
50 11.37 VEGFA JAK3 JAK1

GO Terms for T-Cell Prolymphocytic Leukemia

Cellular components related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.7 TCL1A SMARCB1 SAMHD1 NFKB1 MYC MS4A1
2 protein-containing complex GO:0032991 9.1 TCL1A SMARCB1 MYC MTCP1 CDKN1B ABL1

Biological processes related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.93 VEGFA TCL1A NFKB1 MYC CDKN1B
2 cytokine-mediated signaling pathway GO:0019221 9.87 VEGFA MYC JAK3 JAK1
3 phosphorylation GO:0016310 9.8 JAK3 JAK1 CHEK2 CDKN1B ATM ABL1
4 DNA repair GO:0006281 9.77 SAMHD1 CHEK2 BRCC3 ATM ABL1
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.69 VEGFA TCL1A MTCP1
6 replicative senescence GO:0090399 9.58 CHEK2 ATM
7 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.58 CHEK2 CDKN1B ATM
8 positive regulation of DNA biosynthetic process GO:2000573 9.56 VEGFA MYC
9 positive regulation of response to DNA damage stimulus GO:2001022 9.55 MYC ATM
10 interleukin-15-mediated signaling pathway GO:0035723 9.52 JAK3 JAK1
11 signal transduction in response to DNA damage GO:0042770 9.49 CHEK2 ABL1
12 interleukin-2-mediated signaling pathway GO:0038110 9.48 JAK3 JAK1
13 interleukin-9-mediated signaling pathway GO:0038113 9.46 JAK3 JAK1
14 cell cycle arrest GO:0007050 9.46 MYC CDKN1B ATM ABL1
15 interleukin-21-mediated signaling pathway GO:0038114 9.43 JAK3 JAK1
16 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.43 CHEK2 ATM ABL1
17 cellular response to DNA damage stimulus GO:0006974 9.43 SAMHD1 MYC CHEK2 BRCC3 ATM ABL1
18 DNA damage induced protein phosphorylation GO:0006975 8.8 CHEK2 ATM ABL1

Molecular functions related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.65 JAK3 JAK1 CHEK2 ATM ABL1
2 kinase activity GO:0016301 9.63 JAK3 JAK1 CHEK2 CDKN1B ATM ABL1
3 protein phosphatase binding GO:0019903 9.5 JAK3 JAK1 CDKN1B
4 neuropilin binding GO:0038191 8.96 VEGFA ABL1
5 non-membrane spanning protein tyrosine kinase activity GO:0004715 8.8 JAK3 JAK1 ABL1

Sources for T-Cell Prolymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....